Results 71 to 80 of about 1,458,916 (304)
Arthritis &Rheumatology, EarlyView.Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis +22 more
wiley +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Arthritis &Rheumatology, EarlyView.Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany
, 2023 Annemarie Voss,1 Bianca Kollhorst,2 Katharina Platzbecker,1 Ute Amann,1 Ulrike Haug1,3 1Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 2Department of Biometry and Data Management ...
Platzbecker K +4 more
core
Arthritis &Rheumatology, Accepted Article.Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken +7 more
wiley +1 more source
Direct oral anticoagulants. The story of success
Lets organize a nice funeral for warfarin – told by Eugene Braunwald twenty years ago, when first large scale studies had been planned and started with direct oral anticoagulants (DOACs), earlier called novel oral anticoagulants (NOACS).
Róbert Gábor Kiss +1 more
core +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
British Journal of Clinical Pharmacology, EarlyView.Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
Case Reports in Hematology, 2020 Heparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin.
Mohamed Aon, Omar Al-Shammari
doaj +1 more source
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
, 2019 Background: Over the last ten years, a new class of drugs, known as the direct-acting oral anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy.
Stephanie Kustos, Pius Fasinu
core +1 more source
Applying machine learning to pharmacovigilance data: A proof‐of‐concept study
British Journal of Clinical Pharmacology, EarlyView.Aim Machine learning (ML) applications in pharmacovigilance remain limited and underexplored. Using data from the French National pharmacovigilance database (FNPV), this proof‐of‐concept study aimed to assess the feasibility of using a ML algorithm—eXtreme Gradient Boosting (XGBoost)—combined with SHapley Additive exPlanations (SHAP) analysis, to ...
Romain Barus +6 more
wiley +1 more source
Surreptitious Ingestion of Oral Anticoagulants [PDF]
, 1970 Hypoprothrombinemia secondary to surreptitious ingestion of coumarin or indanedione anticoagulants may be a difficult diagnosis for the unsuspecting physician. Four such case reports are presented.
Van Slyck, Ellis J. +2 more
core +1 more source